Your browser doesn't support javascript.
loading
Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.
Lawson, Rachael A; Yarnall, Alison J; Duncan, Gordon W; Breen, David P; Khoo, Tien K; Williams-Gray, Caroline H; Barker, Roger A; Burn, David J.
Afiliação
  • Lawson RA; Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
  • Yarnall AJ; Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
  • Duncan GW; Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
  • Breen DP; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
  • Khoo TK; John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
  • Williams-Gray CH; School of Medicine & Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Barker RA; School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
  • Burn DJ; John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
J Neurol Neurosurg Psychiatry ; 88(8): 648-652, 2017 08.
Article em En | MEDLINE | ID: mdl-28250029
ABSTRACT

BACKGROUND:

Mild cognitive impairment (MCI) is common in early Parkinson's disease (PD). We evaluated the stability of PD-MCI over time to determine its clinical utility as a marker of disease.

METHODS:

212 newly diagnosed participants with PD were recruited into a longitudinal study and reassessed after 18 and 36 months. Participants completed a range of clinical and neuropsychological assessments. PD-MCI was classified using Movement Disorders Society Task Force level I (Montreal Cognitive Assessment <26) and level II (using cut-offs of 1, 1.5 and 2SD) criteria.

RESULTS:

After 36 months, 75% of participants returned; 8% of patients had developed a dementia all of which were previously PD-MCI. Applying level I criteria, 70% were cognitively stable, 19% cognitively declined and 11% improved over 36 months. Applying level II criteria (1, 1.5 and 2SD), 25% were cognitively stable, 41% cognitively declined, 15% improved and 19% fluctuated over 36 months. 18% of participants reverted to normal cognition from PD-MCI.

DISCUSSION:

Cognitive impairment in PD is complex, with some individuals' function fluctuating over time and some reverting to normal cognition. PD-MCI level I criteria may have greater clinical convenience, but more comprehensive level II criteria with 2SD cut-offs may offer greater diagnostic certainty.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article